Dacarbazine for Injection USP is a white to an ivory colored solid which is light sensitive. Dacarbazine for Injection USP is reconstituted and administered intravenously (pH 3.0 to 4.0). Dacarbazine for Injection USP is an anticancer agent.Dacarbazine for Injection USP is indicated in the treatment of metastatic malignant melanoma. In addition, Dacarbazine for Injection USP is also indicated for Hodgkin’s disease as a secondary-line therapy when used in combination with other effective agents. Although the exact mechanism of action of Dacarbazine for injection is not known, three hypotheses have been offered:
1.Inhibition of DNA synthesis by acting as a purine analog.
2.Action as an alkylating agent.
3.Interaction with SH groups
India has many manufacturers who manufacture Dacarbazine for Injection USP.To know more contact us.
Store in a refrigerator 2° to 8°C (36° to 46°F). Use within 8 hours of reconstitution. Protect from light.
In Malignant Melanoma
The recommended dosage is 2 to 4.5 mg/kg/day for 10 days. Treatment may be repeated at 4 week intervals.
An alternate recommended dosage is 250 mg/square meter body surface/day IV for 5 days. Treatment may be repeated every 3 weeks.
In Hodgkin’s Disease
The recommended dosage of Dacarbazine for injection in the treatment of Hodgkin’s Disease is 150 mg/square meter body surface/day for 5 days, in combination with other effective drugs. Treatment may be repeated every 4 weeks.An alternative recommended dosage is 375 mg/square meter body surface on day 1, in combination with other effective drugs, to be repeated every 15 days.
Symptoms of anorexia, nausea, and vomiting are the most frequently noted of all toxic reactions. Over 90% of patients are affected with the initial few doses. The vomiting lasts 1 to 12 hours and is incompletely and unpredictably palliated with phenobarbital and/or prochlorperazine. Rarely, intractable nausea and vomiting have necessitated discontinuance of therapy with Dacarbazine for injection. Rarely, Dacarbazine for injection has caused diarrhea. Some helpful suggestions include restricting the patient’s oral intake of food for 4 to 6 hours prior to treatment. The rapid toleration of these symptoms suggests that a central nervous system mechanism may be involved, and usually these symptoms subside after the first 1 or 2 days.
There are a number of minor toxicities that are infrequently noted. Patients have experienced an influenza-like syndrome of fever to 39°C, myalgias and malaise. These symptoms occur usually after large single doses, may last for several days, and they may occur with successive treatments.
Alopecia has been noted as has facial flushing and facial paresthesia. There have been few reports of significant liver or renal function test abnormalities in man. However, these abnormalities have been observed more frequently in animal studies.
Erythematous and urticarial rashes have been observed infrequently after administration of Dacarbazine for injection. Rarely, photosensitivity reactions may occur.